DiaMedica Inc.

DiaMedica Inc.

January 15, 2015 08:02 ET

DiaMedica Appoints David Gurvey as Vice President of Finance

MINNEAPOLIS, MINNESOTA--(Marketwired - Jan. 15, 2015) - DiaMedica Inc. (TSX VENTURE:DMA) today announced the appointment of Mr. David Gurvey as the Company's Vice President of Finance. Mr. Gurvey has more than 13 years of experience working with publicly traded and private companies in senior financial roles.

Mr Gurvey is a Chartered Professional Account (CPA, CMA) and holds a B.Sc with an emphasis on biochemistry. Prior to joining DiaMedica, Mr. Gurvey has held Chief Financial Officer positions with both public and private companies. Mr. Gurvey began his career with Ernst & Young Chartered Accountants.

"We are pleased to have David on the DiaMedica team," said Rick Pauls, DiaMedica's President and CEO. "David's experience with publicly traded companies will be extremely valuable as we further advance DM199. His science background will also allow him to quickly gain the detailed understanding of our products and help advance DiaMedica's business strategy."

"I was attracted to the potential of the Company several years ago and subsequently became a long-term shareholder. I am thrilled to be joining DiaMedica and look forward to working with the leadership team on the exciting next phase of development." said Mr. Gurvey.

The Company issued Mr. Gurvey 100,000 stock options in accordance with the Stock Option Plan at an exercise price of CAD $0.10 and a term of 10 years. The options are subject to acceptance by the TSX Venture Exchange.

DiaMedica also announces that it has converted approximately $1 million in account payables to long-term debt.

About DiaMedica

DiaMedica is a publicly traded (TSX VENTURE:DMA) development stage biopharmaceutical company primarily focused on large unmet diseases including novel approaches to treat vascular and metabolic diseases. DiaMedica's lead product, DM199, is recombinant human tissue kallikrein-1 protein (rhKLK1). DiaMedica's common shares are listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.


The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. Forward looking statements in this news release include, but are not limited to, the Company's objectives, goals, future plans and statements regarding its restructuring measures. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to: uncertainties associated with raising additional capital, its ability to satisfy its current contractual obligations; timing and success of implementing current proposed restructuring measaures and any future measures; and the additional risk factors described in detail in the Prospectus and DiaMedica's other filings with the Canadian securities regulators, all of which are available on SEDAR (www.sedar.com). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.

Contact Information

  • DiaMedica Inc.
    Rick Pauls
    Chief Executive Officer

    DiaMedica Inc.
    One Carlson Parkway, Suite 124
    Minneapolis, MN